Proven results
with Attruby

Actor portrayals.

Attruby is a TTR Transthyretin, pronounced "trans-thy-retin," or TTR is an important protein that helps transport thyroxine, a thyroid hormone, and retinol (vitamin A) in your body. stabilizer that treats wild-type Wild-type refers to a form of ATTR-cardiac amyloidosis that people develop as they age. and hereditary A characteristic or trait that is passed down through your family in your genes.
ATTR-cardiac amyloidosis

Attruby slows the buildup of abnormal proteins called amyloid fibrils

by attaching to TTR
and stabilizing the bonds holding the protein together.

Stable TTR means:

TTR remains whole, so it's less likely to break down and reform into the amyloid fibrils that cause ATTR-cardiac amyloidosis

How can I tell if Attruby is stabilizing my TTR?

Ask your doctor about a serum TTR test, also known as a prealbumin blood test This test measures transthyretin (TTR) levels, also known as prealbumin. It measures overall health status. The higher your number is on the scale, the more stable TTR there is in your body.
Your doctor will help you understand how the test works and share
what an appropriate level looks like for you
The higher your number on the scale, the more stable TTR there
is in your body

Curious about the role of TTR in ATTR-cardiac amyloidosis?

Learn About TTR

The science behind Attruby

Attruby is a stabilizer that works by strengthening the bonds that hold the protein

transthyretin (TTR)

together.

With the bonds stabilized, TTR is less likely to break down, which in turn, prevents the
formation of the amyloid fibrils

that cause ATTR-cardiac amyloidosis.

of TTR proteins were stabilized with Attruby as seen in laboratory tests

TTR stabilization was seen as early as 28 days, through 30 months, in laboratory tests of
people taking Attruby.

Understanding how Attruby was studied

How effective and safe Attruby was for people with
ATTR-cardiac amyloidosis was assessed in a clinical study.

Attruby is proven to positively impact:

Survival
Hospitalization due to heart issues
Quality of life

See Results

Exploring the study

611

People participated

This study is one of the largest for
ATTR-cardiac amyloidosis
77

Average age

The average age of people in the study with
wild-type Wild-type refers to a form of ATTR-cardiac amyloidosis that people develop as they age. or hereditary A characteristic or trait that is passed down through your family in your genes. ATTR-cardiac
amyloidosis was 77 years old
409

People took Attruby

Out of 611 people, 409 took Attruby and 202 received placebo A placebo is a pill that has no actual treatment in it but is given to a person so they assume they are receiving real medicine.
30

Months

The study lasted for 30 months
90%

Were male

10%

Were female
- 10% had hereditary ATTR-CM
- 58% had a history of atrial fibrillation A heart condition that causes an irregular and sometimes abnormally fast heart rate.
- 19% had a permanent pacemaker

How well Attruby worked was calculated by taking specific measures at the beginning and comparing them with those same measures at the end of the study.

Primary measures, which helped determine how well Attruby worked over the 30-month study, included a combined measure of:

Survival
Hospital visits due to heart issues

Additional assessments included:

Walking distance in 6 minutes, which measures heart function and exercise capacity

How far a person could walk at the beginning of the study
was compared with how far they could walk after 30 months
of treatment.
Quality of life, which was measured using a
questionnaire specifically designed for people
who have cardiomyopathy

Quality of life was measured using a questionnaire known
as the Kansas City Cardiomyopathy Questionnaire (KCCQ).
It consists of 23 questions that help your doctor get a clearer picture of your quality of life by reviewing the frequency and burden of symptoms, and how you are doing physically
and emotionally.
Blood test measurements Your doctor may order blood tests so they can better understand the health of your heart in  ATTR-cardiac amyloidosis. The most common tests are a serum TTR test (also known as a prealbumin blood test) and NT-proBNP test, which is a measure of heart health. ; when your
heart isn’t working properly, your body has a
biochemical response which can be assessed

Some tests include:
- TTR or prealbumin blood test This test measures transthyretin (TTR) levels, also known as prealbumin. It measures overall health status. The higher your number is on the scale, the more stable TTR there is in your body.
- NT-proBNP N-terminal pro B-type natriuretic peptide (NT-proBNP) is a hormone that can be measured to help diagnose heart failure.

Attruby delivered rapid and sustained results in wild-type Wild-type refers to a form of ATTR-cardiac amyloidosis that people develop as they age. and hereditary A characteristic or trait that is passed down through your family in your genes.
ATTR-cardiac amyloidosis

In a 30-month clinical study,

people treated with Attruby did significantly better than those not taking Attruby
(placebo

). The results were based on a combined measure of survival and hospitalizations due to heart issues.

When comparing results in people treated with and without Attruby at 30 months,
people taking Attruby achieved:

months

Positive impact on survival and hospitalizations due to heart issues
were observed as early as 3 months.

Positive impact on quality of life

When comparing health-related quality of life measures in people treated with and without Attruby in a 30-month clinical study, people treated with Attruby reported better results^†:

Symptoms

Reduced shortness of breath and fatigue, Fatigue describes an overall feeling of tiredness or lack of energy. It’s not the same as being drowsy or sleepy. When you're fatigued, you lack energy to do daily activities. as well as less swelling in the legs, ankles, and feet.
Physical abilities

Including the ability to walk 1 block on level ground or climb up a short flight
of stairs without stopping.^‡
Social engagement

People were able to experience better overall enjoyment of life, such as visiting with family or friends.^§

Positive impact on quality of life was first observed after 3 months.^*

^*The treatment effect of Attruby on health status was assessed using the Kansas City Cardiomyopathy Questionnaire-Overall Summary
(KCCQ-OS) score composed of the physical limitation, symptom, social limitation, quality of life, and self-efficacy domains, respectively.

^†At the end of the 30-month study of adults with ATTR-cardiac amyloidosis, on average, people experienced a decline in their KCCQ-OS, a measure
of quality of life.

^‡Other physical improvements included ability to do household chores and showering or bathing independently

^§This also included better engagement with their hobbies or enjoying intimate relationships.

Feel confident starting Attruby

Attruby offers proven clinical safety

Possible side effects may include diarrhea and abdominal pain. For most people, these side effects were mild and went away, so they could continue taking Attruby.

Questions about Attruby?

Explore the most commonly asked questions about Attruby from people living with
ATTR-cardiac amyloidosis and their care partners.

See the FAQs

What is Attruby